Your Location：Home >Products >Custom peptide >196078-30-5
Product Details
|
Description |
Pramlintide acetate is an injectable human amylin analog used in the treatment of both type 1 and type 2 diabetes, in conjunction with insulin. Differing from its parent precursor, amylin, it is a stable synthetic analog with improved solubility and elimination of aggregation due to substitutions at Ala-25, Ser-28, and Ser-29 with prolines. Pramlintide acetate's mechanism of action mimics amylin, a neurohormone cosecreted with insulin, contributing to glucose homeostasis. It inhibits glucagon, slows gastric emptying, and induces postprandial satiety, leading to weight loss in patients with type 2 diabetes. |
|
Chemical Properties |
Pramlintide acetate is White Solid |
|
Uses |
While effective, Pramlintide acetate is contraindicated in patients with gastroparesis, those taking drugs affecting gastrointestinal motility, and individuals prone to hypoglycemia. Common adverse events include nausea, vomiting, anorexia, headache, abdominal pain, fatigue, dizziness, coughing, and pharyngitis. Administered subcutaneously, it is refrigerated before opening and can be kept at room temperature for up to 28 days after opening. The dosage varies for type 1 and type 2 diabetes, with Pramlintide acetate serving as an adjunct to insulin therapy, offering benefits in glucose control, appetite management, and potential weight loss. |
|
Brand name |
Symlin (Amylin). |
InChI:InChI=1/C171H269N51O53S2/c1-21-81(12)130(163(268)207-110(56-78(6)7)169(274)222-53-33-42-118(222)170(275)221-52-32-41-117(221)160(265)219-135(89(20)230)167(272)206-109(66-125(180)238)151(256)212-128(79(8)9)161(266)186-68-126(239)192-111(70-223)154(259)203-107(64-123(178)236)152(257)218-134(88(19)229)166(271)195-98(136(181)241)57-92-43-45-94(231)46-44-92)214-159(264)116-40-31-51-220(116)127(240)69-187-141(246)101(58-90-34-24-22-25-35-90)199-148(253)105(62-121(176)234)201-149(254)106(63-122(177)235)202-155(260)112(71-224)209-156(261)113(72-225)208-146(251)103(60-93-67-184-75-188-93)205-162(267)129(80(10)11)213-150(255)100(55-77(4)5)198-145(250)102(59-91-36-26-23-27-37-91)200-147(252)104(61-120(175)233)196-137(242)82(13)189-144(249)99(54-76(2)3)197-142(247)96(39-30-50-185-171(182)183)193-143(248)97(47-48-119(174)232)194-165(270)132(86(17)227)215-138(243)83(14)190-157(262)114(73-276)211-168(273)133(87(18)228)216-139(244)84(15)191-164(269)131(85(16)226)217-153(258)108(65-124(179)237)204-158(263)115(74-277)210-140(2
Two new agents with unique mechanisms of action increase the options for improving glycemic control in patients with diabetes mellitus. Exenatide (Byetta—Amylin; Lilly) is a synthetic form of a protein found in the saliva of the Gila monster, a large lizard that is native to Mexico and the southwestern United States. It mimics the action of incretins such as glucagon-like peptide-1 (GLP-1), and the amino acid sequence of exenatide (sometimes designated as an incretin-mimetic agent) partially overlaps that of human GLP-1.
The limit of quantitation for determining spiked authentic samples of degradation products was shown to be approximately 0.1% (relative to intact pramlintide) for both methods. Relative retention times for known pramlintide degradation products were determined for both the RP- and SCX-HPLC methods, demonstrating the selectivities of the 2 methods as well as the orthogonality of the information.
CAS：141732-76-5
CAS：40077-57-4
CAS：83150-76-9
CAS：214047-00-4
